In VivoSome 10 years since Japan introduced policies, regulations and review pathways to encourage the development and commercialization of cell therapy products, the country has recently modified some regul
Pink SheetSome 10 years since Japan introduced policies, regulations and review pathways to encourage the development and commercialization of cell therapy products, the country has recently modified some regul
ScripSome 10 years since Japan introduced policies, regulations and review pathways to encourage the development and commercialization of cell therapy products, the country has recently modified some regul
Pink SheetA novel regenerative medicine for a severe cardiovascular disease, initially granted a conditional approval in Japan almost a decade ago, will exit the market due to challenges meeting the terms of th